Contact: Bill Schaller
Dana-Farber Cancer Institute
Caption: Pasi Janne, M.D., Ph.D., and colleagues are reporting in the New England Journal of Medicine that non-small cell lung cancer patients whose tumor cells had an abnormal ALK gene fared better if treated with crizotinib, a targeted therapy, than with traditional chemotherapy.
Credit: Sam Ogden
Usage Restrictions: None
Related news release: Targeted therapy boosts lung cancer outcomes